> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tang Capital Management Holds 5.7% Of Ardelyx After Its Drug Outlook Cuts
- URL: https://www.bullished.co/tang-capital-management-holds-5-7-of-ardelyx-after-its-drug-outlook-cuts-950df3f4/
- Published: 2026-11-17T22:41:26.000Z
- Updated: 2026-11-17T22:41:26.000Z
- Description: Kevin Tang reported shared authority over the same shares, while Ardelyx faces a lawsuit over its medicines' growth prospects.
- Author: Matteo Parrino
- Tags: SEC Filings, ARDX, Industry: Healthcare

Tang Capital Management reported a [5.7% stake](https://www.sec.gov/Archives/edgar/data/0001232621/000121465926014519/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Ardelyx](https://www.bullished.co/tag/ardx/), a biopharmaceutical company selling prescription medicines for bowel and kidney conditions, in a passive ownership disclosure filed Tuesday. The position comes after Ardelyx reduced its commercial outlook in August and faces a securities lawsuit alleging it overstated its drugs' growth prospects.

## Shared Authority Over 14.3 Million Shares

The position totaled 14,336,247 common shares as of November 9\. Kevin Tang, Tang Capital Management's manager, reported the identical holding because he and the firm share voting and sale authority with related entities.

The holdings belong to Tang Capital Partners, Tang Capital Partners International, Tang Capital Partners III and Tang Capital Partners IV. Their respective positions were 2,663,183 shares, or 1.1%; 4,892,410 shares, or 1.9%; 3,350,677 shares, or 1.3%; and 3,429,977 shares, or 1.4%.

Tang Capital Management is general partner of the first two partnerships. Tang is chief executive of the latter two corporations, which Tang Capital Partners indirectly owns in full.

The reporting parties [certified a passive](https://www.sec.gov/Archives/edgar/data/0001232621/000121465926014519/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) purpose: they did not acquire or hold the shares to change or influence Ardelyx's control. The ownership percentages use 251,372,553 common shares outstanding as of October 27.

## Insurance Restrictions Hit The Outlook

Ardelyx [cut its full-year](https://www.businesswire.com/news/home/20261116726073/en/ARDELYX-NASDAQ-ARDX-CLASS-ACTION-DEADLINE-TODAY-Faruqi-Faruqi-LLP-Reminds-Investors-of-November-16-2026-Lead-Plaintiff-Deadline?ref=bullished.co) IBSRELA forecast in August and withdrew its long-term XPHOZAH revenue guidance. The company attributed slower IBSRELA patient starts to insurers restricting access and cited uncertainty over XPHOZAH's future growth.

Shares fell about 18% on August 7, from $4.87 to $4.00.

A securities [lawsuit alleges](https://www.globenewswire.com/news-release/2026/11/16/3403868/0/en/bronstein-gewirtz-grossman-llc-urges-ardelyx-inc-investors-to-act-class-action-filed-alleging-investor-harm.html?ref=bullished.co) Ardelyx and certain officers exaggerated the medicines' prospects while insurance approval requirements delayed patients starting treatment and prescriptions being filled. It seeks damages for alleged federal securities-law violations for investors who bought Ardelyx securities from January 13, 2025 through August 6, 2026.

## Two Medicines, One Active Ingredient

Both medicines use tenapanor, which Ardelyx discovered and developed. IBSRELA is approved in the United States for adults with irritable bowel syndrome with constipation. XPHOZAH lowers blood phosphorus in adults with chronic kidney disease on dialysis who respond poorly to phosphate binders or cannot tolerate them.

Ardelyx uses its own specialty sales team and third-party contract manufacturers. It licenses tenapanor to partners in Canada, Japan and China, earning upfront payments, milestones and royalties, and charging to supply finished medicine or its drug substance.

The company is also conducting a late-stage tenapanor trial for chronic idiopathic constipation.

The deadline to seek appointment as lead plaintiff was Monday; investors need not serve in that role to participate in any recovery, according to the [law firms' notice](https://www.businesswire.com/news/home/20261116726073/en/ARDELYX-NASDAQ-ARDX-CLASS-ACTION-DEADLINE-TODAY-Faruqi-Faruqi-LLP-Reminds-Investors-of-November-16-2026-Lead-Plaintiff-Deadline?ref=bullished.co).

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — TANG CAPITAL MANAGEMENT, LLC re: Ardelyx, Inc. (ARDX)](https://www.sec.gov/Archives/edgar/data/0001232621/000121465926014519/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Ardelyx Inc. (NASDAQ:ARDX) : Articles :: Law360](https://www.law360.com/companies/ardelyx-inc?article%5Frelated%5Fcontent=1&ref=bullished.co) — law360.com
- [ARDELYX (NASDAQ: ARDX) CLASS ACTION DEADLINE TODAY: Faruqi & Faruqi, LLP Reminds Investors of November 16, 2026 Lead Plaintiff Deadline](https://www.businesswire.com/news/home/20261116726073/en/ARDELYX-NASDAQ-ARDX-CLASS-ACTION-DEADLINE-TODAY-Faruqi-Faruqi-LLP-Reminds-Investors-of-November-16-2026-Lead-Plaintiff-Deadline?ref=bullished.co) — businesswire.com
- [Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc.](https://www.globenewswire.com/news-release/2026/11/16/3403868/0/en/bronstein-gewirtz-grossman-llc-urges-ardelyx-inc-investors-to-act-class-action-filed-alleging-investor-harm.html?ref=bullished.co) — globenewswire.com
- [ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law](https://www.prnewswire.com/news-releases/ardx-investors-have-opportunity-to-lead-ardelyx-inc-securities-fraud-lawsuit-with-sbs-law-302939816.html?ref=bullished.co) — prnewswire.com

### More on Ardelyx

- [Ardelyx Stock Surges 6%, Adding $44 Million, After Quarterly Loss Nearly Disappears](https://www.bullished.co/ardelyx-stock-surges-6-adding-44-million-after-quarterly-loss-nearly-disappears-caf9ef3f/)
- [Ardelyx CEO Says 'We All Need To Be Patient' On Xphozah Outlook As Revenue Rises 7% To $29.2 Million](https://www.bullished.co/ardelyx-ceo-says-we-all-need-to-be-patient-on-xphozah-outlook-as-revenue-rises-7-to-29-2-719d7092/)
- [Ardelyx Faces A New Securities Class Action Reaching Back To January 2025](https://www.bullished.co/ardelyx-faces-a-new-securities-class-action-reaching-back-to-january-2025-77e98c53/)

[All Ardelyx (ARDX) coverage →](https://www.bullished.co/tag/ardx/)